Skip to content
Open access

Activation-induced cytidine deaminase sustains glycolytic flux through MYST1 acetyltransferase-dependent lactylation in hepatocellular carcinoma.

Sep 2026 · Journal of Biological Chemistry · pp. 113591 · 0 citations · 36 references
Medicine

TL;DR

A previously unrecognized AID-MYST1-lactylation-glycolysis axis that underpins the metabolic plasticity of HCC is delineated, offering a promising therapeutic strategy to target metabolic dependencies in liver cancer.

Abstract

Hepatocellular carcinoma (HCC) exhibits profound metabolic reprogramming, yet the mechanisms that sustain persistent glycolytic flux remain poorly defined. In this study, we identify activation-induced cytidine deaminase (AID) as a non-canonical metabolic regulator that drives HCC progression through a self-reinforcing feedforward loop. AID is significantly upregulated in HCC tissues, where its expression correlates with aggressive clinical features and poor prognosis. Mechanistically, AID functions as a molecular scaffold, recruiting the acetyltransferase MYST1 via its 95-198 amino acid domain. This AID-MYST1 complex utilizes Lac-CoA as a substrate to mediate site-specific non-histone lactylation of the rate-limiting glycolytic enzymes GLUT1 (K6) and PGK1 (K6). These modifications markedly enhance the enzymatic activities of GLUT1 and PGK1, thereby accelerating glycolytic flux. Critically, this activation establishes a metabolic positive feedback loop: the intensified glycolysis leads to excessive lactate and Lac-CoA accumulation, which in turn fuels further AID/MYST1-dependent lactylation. This self-sustaining circuitry not only maintains high glycolytic energy production but also sequentially drives the expression of oncogenic drivers, ultimately remodeling the tumor microenvironment (TME). Functionally, disruption of the AID-MYST1-lactylation axis either through genetic ablation of lactylation sites or pharmacological intervention effectively breaks this vicious cycle, impairing glycolysis and suppressing tumor growth in vitro and in vivo. Furthermore, dual inhibition of AID and glycolysis exerts robust synergistic anti-tumor effects. Collectively, our findings delineate a previously unrecognized AID-MYST1-lactylation-glycolysis axis that underpins the metabolic plasticity of HCC, offering a promising therapeutic strategy to target metabolic dependencies in liver cancer.

Read PDF

Similar papers

Open access Aug 2026

The KAT2/HDACⅡa-PGK-ALDO axis constitutes a dual degradation inhibition cascade links energy stress to glycolytic amplification.

A metazoan-conserved dual degradation inhibition cascade whereby energy stress coordinates acetylation-phosphorylation crosstalk that simultaneously enhances glycolytic output and suppresses two protein degradation systems is reported.

Chao-Gang Wang, Mingyang Du, Yutong Liu et al. · 0 citations
Sep 2026

Auto-S-fatty acylation of PKM2 regulates its tetramerization and glycolytic metabolism in cancer cells.

Cancer cells rely on aerobic glycolysis to fuel proliferation, yet how lipid metabolism dynamically regulates glycolysis remains incompletely understood. Here, we identify pyruvate kinase M2 (PKM2) is regulated by auto-S-fatty acylation. Using bioorthogonal chemical reporters, we demonstrate that PKM2 is S-fatty acylat...

Chen Miao, Zhen Wang, Ke-Lin Li et al. · 0 citations
Sep 2026

METTL15-mediated m4C modification regulates glucose metabolic reprogramming via c-Myc-dependent mechanisms and promotes hepatocellular carcinoma progression.

Although aerobic glycolysis is a hallmark of hepatocellular carcinoma (HCC) progression, the underlying epitranscriptomic mechanisms remain poorly understood. Here, we identify METTL15, an N4-methylcytidine (m4C) RNA methyltransferase, as a novel oncogenic driver of this metabolic reprogramming. METTL15 is significantl...

Longhui Xie, Ken Ning, Yu-Hu Wang et al. · 0 citations
Open access Sep 2026

FBP1‐Mediated Compartmentalization of Glycolytic Enzyme Complexes Suppresses PKM2 Function to Ameliorate MASLD Progression

It is shown that FBP1 is consistently downregulated during MASLD progression, with a progressive decline from MASL to MASH in clinical specimens and key preclinical models, and the FBP1‐PKM2 interaction is identified as a novel candidate intervention target for MASLD.

Bu-Song Wang, Yi-Ping Tang, Na Li et al. · 0 citations
Open access Sep 2026

Transketolase-like 1 potentiates PD-1 blockade in hepatocellular carcinoma by glycolysis to prime dendritic cell lactylation

Hepatocellular carcinoma (HCC) exhibits a suboptimal response to immune checkpoint blockade (ICB) therapy; to overcome this resistance, we aimed to delineate key immune resistance factors via multi-omics analysis, develop strategies to block their immunosuppressive axes, and engineer a targeted nanosystem to enhance im...

Heng-Song Cao, Tian Huang, Yue Chai et al. · 0 citations
Review Open access Sep 2026

From metabolic antagonism to homeostatic restoration: rewiring hepatic stellate cell bioenergetics for liver fibrosis reversal

Emerging evidence has redefined metabolic reprogramming in hepatic stellate cells (HSCs) from a mere energy-supporting process to an active driver of liver fibrosis. Unlike conventional descriptions that focus on isolated pathway alterations, recent advances show that activated HSCs coordinate a multi-layered metabolic...

Xin-Yue Lu, Zi-Long Li · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.